In this talk at the Festival of Genomics and Biodata, BLOODPAC’s Executive Director Lauren C. Leiman will speak on BLOODPAC's work in creating liquid biopsy analytical validation protocols through collaboration between key stakeholders, including assay developers, biopharmaceutical companies, academic institutions, not-for-profits, and regulatory agencies. She will also describe the importance of frameworks and standards, including industry-specific lexicons, to drive clinical utility studies for emerging liquid biopsy applications such as MRD and MCED and touch on BLOODPAC's progress in defining best practices for clinical validation for MRD and MCED assays.